Concepedia

Floyd Jones

FJ

Statistics

Publications

17

Citations

1.6K

H-Index

14

Active since

1945

Affiliations

Alexion Pharmaceuticals (United States)(Current)

Fondazione IRCCS Istituto Neurologico Carlo Besta

University of Cincinnati

University of Miami

University College London

Floyd Jones is an author at Alexion Pharmaceuticals (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Publications per year

1945–2025

17

Publications

17

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

, , +6

Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial

James M. Chamberlain, Jaideep Kapur, Shlomo Shinnar et al. · The Lancet · 2020 · 235 citations · Full text

, , +12

The Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) Study Protocol

Daniel Woo, Jonathan Rosand, Chelsea S. Kidwell et al. · Stroke · 2013 · 118 citations · Full text

, , +11

Five cases of alpha chain disease

W F Doe, K. Henry, J R Hobbs et al. · Gut · 1972 · 94 citations · Full text

, , +12

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 79 citations · Full text

, , +9

1–5 of 17